Marketing: Page 2


  • Group of people working in a modern board room with augmented reality interface, all objects in the scene are 3D.
    Image attribution tooltip
    piranka via Getty Images

    Ultragenyx sells rare disease drug royalties to Canadian pension fund

    In exchange for $500 million, the fund, called OMERS, will get a 30% royalty on future sales of Ultragenyx’s drug Crysvita in the U.S. and Canada, where it’s approved to treat two rare conditions.

    By July 15, 2022
  • A 3D illustration of human lungs.
    Image attribution tooltip
    yodiyim via Getty Images

    Royalty Pharma buys rights to top-selling GSK drug in pair of deals

    The prolific biopharma dealmaker is paying Theravance $1.1 billion and Innoviva $282 million to acquire rights to royalties on GSK’s asthma and COPD drug Trelegy Ellipta.

    By Kristin Jensen • July 14, 2022
  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    BioMarin's hemophilia gene therapy recommended for approval in Europe

    The decision brings what could be the first approved hemophilia gene therapy, Roctavian, closer to market, after a series of regulatory setbacks that have delayed its arrival. 

    By June 24, 2022
  • A 3D rendered image of a neuron cell network on black background.
    Image attribution tooltip
    koto_feja via Getty Images

    Amylyx's ALS drug gets approved in Canada

    The Massachusetts-based biotech is awaiting a decision in the U.S., where the FDA recently extended its review after agency advisers narrowly voted against the treatment.

    By June 13, 2022
  • Line graph with collage image of headshots in the background
    Image attribution tooltip
    Permission granted by Fizkes, OM1
    Sponsored by OM1

    Real-world data: A health equity lens for research

    Arising from the circumstances in which people grow, live, work and age, and the systems put in place to deal with illness, these health inequities are avoidable. 

    By Jessica Paulus, ScD, Senior Director, Epidemiology, OM1 • June 13, 2022
  • FTC
    Image attribution tooltip
    Carol Highsmith. (2005). "Apex Bldg." [Photo]. Retrieved from Wikimedia Commons.

    FTC to investigate CVS Caremark, others in probe of PBM business practices

    The decision to launch an inquiry reversed a vote earlier this year, when FTC commissioners had deadlocked over whether to look into the drug pricing middlemen.

    By Rebecca Pifer • June 7, 2022
  • Image attribution tooltip
    Amarin

    Amarin turns to job cuts as generics challenge its heart pill

    Facing greater competition and declining sales in the U.S., the drugmaker is laying off about 40% of its workforce as part of an effort to save $100 million over the next year.

    By June 6, 2022
  • Regeneron buys control of cancer drug Libtayo from Sanofi

    The biotech, which has been partnered with Sanofi for years, will pay $900 million upfront to gain sole control of the cancer immunotherapy.

    By Updated June 2, 2022
  • Image attribution tooltip
    Maddie Meyer via Getty Images

    Moderna vaccine sales surpass expectations as company looks to fall boosters

    The trajectory of COVID-19 vaccine sales is now harder to predict amid questions about the rollout of additional doses and whether purchasing in the U.S. might shift from the federal government to private payers.

    By May 4, 2022
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb

    Bristol Myers wins FDA approval for first drug to treat inherited heart condition

    Bristol Myers paid $13 billion to acquire the drug's maker, MyoKardia, and expects it to become a blockbuster. But a tricky dosing regimen, as well as safety concerns, could challenge the pharmaceutical giant's lofty forecast. 

    By April 28, 2022
  • A photo of Biogen's Alzheimer's drug Aduhelm
    Image attribution tooltip
    Permission granted by Biogen

    Biogen pulls European application for Aduhelm in another setback for the Alzheimer's drug

    In a letter to regulators, Biogen said it chose to withdraw its approval filing after discussions with the EMA, which previously found the data supporting Aduhelm to be lacking.

    By , April 22, 2022
  • department of justice building
    Image attribution tooltip
    bpperry via Getty Images

    DOJ cracks down on 'largest and most wide-ranging' COVID-19 fraud

    Defendants, including doctors, medical business executives and fake vaccination card manufacturers, caused nearly $150 million in false billings to federal programs, the DOJ said. 

    By Rebecca Pifer • April 21, 2022
  • Image attribution tooltip
    Permission granted by GoodRx
    Sponsored by GoodRx

    Inflation is forcing prioritization of healthcare spending — are you ready?

    Inflation means your customers' money doesn't travel as far as it did a few weeks ago.

    April 18, 2022
  • A child plays EndeavorRx on a tablet. The digital therapeutic intended to improve attention in kids with ADHD.
    Image attribution tooltip
    Permission granted by Akili Interactive
    Deep Dive

    Can digital therapeutics be profitable?

    Licensing deals with pharmaceutical companies were an early strategy for digital health companies, but not all of them have lasted.

    By Elise Reuter • April 11, 2022
  • Image attribution tooltip

    adobe.com/Tierney

    Sponsored by Acceleration Point

    The power of alerts

    As medical affairs continues to invest in systems and data, it can quickly become overwhelming to keep up with it all.

    April 11, 2022
  • Image attribution tooltip
    Getty Images

    Medicare finalizes policy limiting coverage of Biogen Alzheimer's drug

    Biogen said it is considering its options following CMS' decision, which restricts reimbursement of Aduhelm to patients enrolled in a randomized clinical trial. 

    By Updated April 7, 2022
  • Sponsored by OM1

    A new approach for post-marketing safety studies

    The large quantity of digitized healthcare data in the U.S. presents an enormous opportunity to shift dramatically how post-marketing safety studies can and should be conducted.

    By Stefan Weiss, MD, MHSc, MBA, Managing Director of Dermatology, OM1 • April 4, 2022
  • The outside of an AbbVie building, with the company's logo displayed.
    Image attribution tooltip
    AbbVie
    Deep Dive // Patent thickets

    Two decades and $200 billion: AbbVie's Humira monopoly nears its end

    Biosimilar copies of Humira will arrive in the U.S. beginning early next year, testing both AbbVie and the market potential for knockoff biologic drugs.

    By March 17, 2022
  • A child plays EndeavorRx on a tablet. The digital therapeutic intended to improve attention in kids with ADHD.
    Image attribution tooltip
    Permission granted by Akili Interactive

    Akili, with plans to go public, prepares to ramp up marketing of video game treatment

    "We've proven that foundation and now it's time to run and scale," said CEO Eddie Martucci. The company is going public through a $1 billion SPAC, rather than a traditional IPO.

    By Elise Reuter • March 10, 2022
  • The outside of an AbbVie building, with the company's logo displayed.
    Image attribution tooltip
    AbbVie
    Patent thickets

    AbbVie holds off another Humira challenger with Alvotech deal

    A settlement will allow the Iceland-based drugmaker to launch its Humira copycat, currently under FDA review, in the U.S. beginning next July.

    By March 9, 2022
  • Image attribution tooltip
    Novo Nordisk

    Novo sees fast growth ahead of obesity drugs despite production hurdles

    The Danish drugmaker aims to triple sales of its weight loss treatments Wegovy and Saxenda by 2025. But first, Novo needs to resolve manufacturing constraints that have slowed the former drug's launch. 

    By March 4, 2022
  • A person receives a blood glucose reading through DarioHealth's smartphone app
    Image attribution tooltip
    Permission granted by DarioHealth

    Sanofi partners with digital health company DarioHealth

    The deal with DarioHealth is one of several digital health investments by the French pharma company in recent years, although not all have panned out.

    By Elise Reuter • March 2, 2022
  • A view of Moderna headquarters on May 08, 2020 in Cambridge, Massachusetts.
    Image attribution tooltip
    Maddie Meyer via Getty Images

    Moderna sued for allegedly infringing patents tied to COVID-19 vaccine

    Arbutus and partner Genevant claim Moderna's coronavirus shot uses delivery technology covered by six patents they hold, an allegation Moderna denies. 

    By Feb. 28, 2022
  • Federal Trade Commission Chair Lina Khan voted in favor of the study.
    Image attribution tooltip
    Retrieved from FTC.

    FTC deadlocks on vote to launch study into PBM practices

    The antitrust agency won't study pharmacy benefit managers' pricing and contract practices as proposed, after a 2-2 vote by commissioners Thursday.

    By Samantha Liss • Feb. 17, 2022
  • Seagen shares sink as sales outlook of cancer drug disappoints

    The biotech is predicting sales of Tukysa, its new breast cancer drug, will remain flat or fall in 2022 as competition increases from AstraZeneca's rival medicine Enhertu.

    By Feb. 10, 2022